Please login to the form below

Not currently logged in
Email:
Password:

mergers and acquisitions

This page shows the latest mergers and acquisitions news and features for those working in and with pharma, biotech and healthcare.

Pfizer takeover rumour ignites Amarin shares

Pfizer takeover rumour ignites Amarin shares

which found that the drug cut the risk of heart attacks and stroke by 25% in high-risk cardiovascular patients. ... Smaller acquisitions could well be on the cards however, with Bourla suggesting that Pfizer will be “aggressive” in business

Latest news

  • Lilly adds to pharma M&A run with $8bn Loxo buy-out Lilly adds to pharma M&A run with $8bn Loxo buy-out

    Loxo also has a promising pipeline, which includes LOXO-292, an oral RET inhibitor being studied across multiple tumour types,   and which was recently granted FDA Breakthrough Therapy designation,   and could ... Gilead, Amgen and Biogen are among

  • BMS and Celgene deal sparks debate on pharma profit motive, more M&A BMS and Celgene deal sparks debate on pharma profit motive, more M&A

    Mergers that mean more money for drug company CEOs while patients pay the price are not a solution to skyrocketing drug costs,” she said. ... Two companies mentioned as potential likely buyers in the market are AbbVie and Merck &Co.

  • Pharma’s R&D productivity sinks to a new low Pharma’s R&D productivity sinks to a new low

    The increase in average cost to develop and win marketing approval for a new drug is behind the declining returns. ... Despite the significantly better rate of return for these companies, most big pharma companies won’t automatically opt for mergers

  • GSK buys cancer firm Tesaro for $5.1bn GSK buys cancer firm Tesaro for $5.1bn

    Following behind are two other immuno-oncology candidates, TSR-022 targeting the TIM-3 checkpoint and ant-LAG3 candidate TSR-033. ... They at currently being tested alone and in combination with TSR-042 in phase 1 trials involving patients with advanced

  • Healthcare sector bullish despite political uncertainty Healthcare sector bullish despite political uncertainty

    Targeted and gene therapies rated as major advances ahead of Jefferies conference in London. ... There is also a feeling that 2018’s buoyant mergers and acquisitions trend will continue into 2019, at least at the same level and possibly even higher,

More from news
Approximately 13 fully matching, plus 62 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    Mergers and acquisitions - still waiting for the tax-driven wave of activity. ... manufacture and supply of Kymriah. $40m. Development. collaboration. Pfizer. Novartis to develop combination.

  • Change in the pharma industry is inevitable Change in the pharma industry is inevitable

    A high proportion (88%) of change initiatives fail. A similar proportion of business strategies, mergers and acquisitions suffer the same fate. ... However, the bad news is that countless research has clearly demonstrated that only 10-30% of mergers or

  • Deal Watch March 2017 Deal Watch March 2017

    By contrast, as well as five company acquisitions, there are a couple of product acquisitions in our Top 20, which might start to explain where the licences are going. ... Among the company acquisitions, Sartorius paid $320m in cash to acquire the

  • Deal Watch February 2017 Deal Watch February 2017

    Such a shareholder revolt seems more akin to what we have seen previously for company acquisitions rather than for a licensing transaction. ... Future deals to look out for? Looking ahead there are likely to be some further significant acquisitions in

  • Deal Watch January 2017 Deal Watch January 2017

    Actelion, Johnson &Johnson, Sanofi, Takeda and more feature in this month's pharma deals round-up. ... 250. Vertex. Merck KGaA. Collaboration. VX 970 VX 803 and 2 others ATR inhibitors.

More from intelligence
Approximately 12 fully matching, plus 59 partially matching documents found.

Latest appointments

  • New hires at Mundipharma, Sinclair Pharma and Relay Therapeutics New hires at Mundipharma, Sinclair Pharma and Relay Therapeutics

    Latest movers in pharma. Mundipharma hires new SVP business development and strategic partnerships. ... Cerato brings with him a wealth of business development experience, including in-licensing, out-licensing, alliance management, and mergers and

  • Ipsen bolsters leadership team Ipsen bolsters leadership team

    acquisition of drug candidates, commercial products and companies for the global speciality drug business. ... With expertise in corporate partnering, mergers and acquisitions, pipeline and product portfolio development, legal and IP strategy,

  • IRX Therapeutics appoints Luba Greenwood to its board IRX Therapeutics appoints Luba Greenwood to its board

    Her career has spanned leadership roles in venture investing, business development, mergers and acquisitions, law, consulting and operations. ... Prior to that, she served as senior mergers and acquisitions counsel at Pfizer.

  • Apeiron bolsters management board Apeiron bolsters management board

    With more than 25 years’ experience in initial public offerings, mergers and acquisitions, as well as licensing and financial transactions in the chemical, biotech and pharma industries, Llewellyn-Davies most recently ... During the course of his career

  • Sobi appoints Torbjorn Hallberg as general counsel Sobi appoints Torbjorn Hallberg as general counsel

    He arrives at Sobi will more than 15 years’ experience covering licensing, mergers and acquisitions at pharma groups such as  Ferring and Nycomed. ... Carin Dahlquist (an acting role), head of EMENA Hege Hellström and head of North America Rami Levin.

More from appointments
Approximately 0 fully matching, plus 28 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics